Format

Send to

Choose Destination
See comment in PubMed Commons below
Reprod Biomed Online. 2010 Aug;21(2):186-95. doi: 10.1016/j.rbmo.2010.04.031. Epub 2010 Jun 4.

PGD for all cystic fibrosis carrier couples: novel strategy for preventive medicine and cost analysis.

Author information

1
Institute for Human Reproduction (IHR), 2825 N Halsted St., Chicago, IL 60657, USA. DrTK@infertilityIHR.com

Abstract

Over 1000 children affected with cystic fibrosis (CF) are born annually in the USA. Since IVF with preimplantation genetic diagnosis (PGD) is an alternative to raising a sick child or to aborting an affected fetus, a cost-benefit analysis was performed for a national IVF-PGD program for preventing CF. The amount spent to deliver healthy children for all CF carrier-couples by IVF-PGD was compared with the average annual and lifetime direct medical costs per CF patient avoided. Treating annually about 4000 CF carrier-couples with IVF-PGD would result in 3715 deliveries of non-affected children at a cost of $57,467 per baby. Because the average annual direct medical cost per CF patient was $63,127 and life expectancy is 37 years, savings would be $2.3 million per patient and $2.2 billion for all new CF patients annually in lifetime treatment costs. Cumulated net saving of an IVF-PGD program for all carrier-couples for 37 years would be $33.3 billion. A total of 618,714 cumulative years of patients suffering because of CF and thousands of abortions could be prevented. A national IVF-PGD program is a highly cost-effective novel modality of preventive medicine and would avoid most births of individuals affected with debilitating genetic disease.

Comment in

PMID:
20594975
DOI:
10.1016/j.rbmo.2010.04.031
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center